Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Bell Potter Healthcare Conference 2024
14 slides from Botanix Pharmaceuticals's conference presentation, Nov 19, 2024
Slide 1: Botanix presentation at Bell Potter Healthcare Conference
19 November 2024 Botanix presentation at Bell Potter Healthcare Conference Key highlights • Botanix Founder and Board Executive Director Matt Callahan will be a featured presenter the Bell Potter Healthcare Conference 2024 • The presentation will provide an update in relation to the commercializatio
Slide 2: Cautionary Note on Forward-Looking Statements
For more information, please contact: General enquiries Investor enquiries Media enquiries Corporate Communications Hannah Howlett Haley Chartres Botanix Pharmaceuticals WE Communications H^CK P: +61 8 6555 2945 P: +61 450 648 064 P: +61 423 139 163 investors@botanixpharma.com hhowlett@we-worldwide.
Slide 3: Bell Potter Healthcare Conference 2024
September For personal use only 2024 W W W .B O TA NI X P H A R M A .C O M Botanix Pharmaceuticals Bell Potter Healthcare Conference 2024 www.botanixpharma.com
Slide 4: Botanix overview
Botanix overview For personal use only DERMATOLOGY WORLD CLASS NEW PRODUCT NOW FDA WELL FOCUS TEAM “SOFDRA” APPROVED CAPITALISED New treatments US-based team First and only Approved by ~A$69 million at W W W . B O T A N I X P H A R M A . C O M for underserved responsible for new chemical FDA for the
Slide 5: Corporate Overview
Corporate Overview For personal use only ASX: BOT TRADING INFORMATION Share price A$0.32 6-month low / high A$0.19/0.44 W W W . B O T A N I X P H A R M A . C O M Shares outstanding 1,814,037,788 Market Capitalization A$580m Cash A$69m Debt Nil SUBSTANTIAL SHAREHOLDERS Shareholder % Antares Capital 1
Slide 6: Hyperhidrosis
Hyperhidrosis A medical condition where excessive sweating For personal use only occurs beyond what is needed to maintain normal body temperature W W W . B O T A N I X P H A R M A . C O M ❖ Results from overstimulation of the nervous system (a physiological not psychological condition)1 ❖ 90% of axi
Slide 7: Targeting the patients and the dermatologists in the office
Targeting the patients and the dermatologists in the office and separately accessing the untreated patients For personal use only ~16.1M Hyperhidrosis Patients W W W . B O T A N I X P H A R M A . C O M DIAGNOSED TARGETS NOW HH TARGETS ~7M ~10M Identifying and targeting patients Axillary Hyperhidrosi
Slide 8: Expanding team supports Sofdra commercialisation
Expanding team supports Sofdra commercialisation For personal use only W W W . B O T A N I X P H A R M A . C O M JOHN WALSH SHEETAL SAHEL CHRIS LESOVITZ LEISHA MARTIN Vice President, Sales Vice President, Marketing Chief Financial Officer, USA VP, Quality & Regulatory SALES MARKETING BUSINESS OPERAT
Slide 9: Botanix sales force deployment
Botanix sales force deployment Three Regions: Northeast, Central & West (9 per Region) For personal use only W W W . B O T A N I X P H A R M A . C O M Region Reps Northeast 9 Central 9 West 9 7 Source: AlignMix, IQVIA 12m TRx AD Branded Market
Slide 10: Patient Path - UpScript's fully integrated model
Patient Path - UpScript’s fully integrated model allows patients direct access from anywhere 24/7 Sofdra Patient Path For personal use only W W W . B O T A N I X P H A R M A . C O M Brand/ Patient Registers Completes an Schedules Provides Product page or Logs In Online Medical Appointment Payment In
Slide 11: Expected Sofdra coverage
Expected Sofdra coverage Expected Sofdra Coverage Expected Sofdra Coverage For personal use only Commercial Lives (167M) Including Medicaid/VA/TRICARE (266M) W W W . B O T A N I X P H A R M A . C O M 10% 6% 12% 23% 36% 19% 35% 59% Covered – no restrictions Covered – PA to label or single step edit N
Slide 12: Payer success continues
Payer success continues ❖ Recently announced coverage with Ascent Health, who are responsible for For personal use only ~65M commercial lives ❖ Ascent adds to the existing Payer coverage already completed, or actively being finalised with Payers, who together represent more than 110 million W W W .
Slide 13: Planned commercialization timeline
Planned commercialization timeline ENGAGE ESTABLISH EXPAND SEP OCT NOV DEC JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC For personal use only Patient Experience Program VP, Sales Hired W W W . B O T A N I X P H A R M A . C O M Field Managers Hired Fall Clinical Dermatology Conference All IHhS Pat
Slide 14: Sofdra commercial success is built on pillars
Sofdra commercial success is built on 3 pillars LARGE MARKET AND FRICTIONLESS ACCESS PRODUCT SPEED TO PATIENT 1 ENGAGED POPULATION 2 3 WITH TELEMEDICINE AND ENSURING EVERY REFILL For personal use only AXILLARY HYPERHIDROSIS PATIENTS W W W . B O T A N I X P H A R M A . C O M ~10M PATIENTS SEEKING RX
Botanix Pharmaceuticals — Bell Potter Healthcare Conference 2024 on 6ix